Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
- First Posted Date
- 2022-07-27
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 5000
- Registration Number
- NCT05476926
- Locations
- 🇨🇱
Centro de la Vision, Las Condes, Chile
🇩🇪Universitaetsklinikum Jena, Jena, Germany
🇩🇪Universitaetsklinikum Koeln, Koeln, Germany
A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)
- Conditions
- Interventions
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 12
- Registration Number
- NCT05459129
- Locations
- 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇦🇺Sir Charles Gairdner Hospital; Medical Oncology, Perth, Western Australia, Australia
🇫🇷Institut de Cancérologie de Lorraine, Vandoeuvre-Les-Nancy, France
Screening Study for Participants With Malignant Tumors
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 15000
- Registration Number
- NCT05419375
- Locations
- 🇫🇷
CHU Angers, Service de Pneumologie, Angers, France
🇫🇷CHU Strasbourg - Nouvel Hopital Civil, Strasbourg, France
🇫🇷HIA Sainte Anne - Toulon, Toulon, France
A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 80
- Registration Number
- NCT05419388
- Locations
- 🇨🇿
Masarykuv onkologicky ustav, Brno, Czechia
🇦🇺Coffs Harbour Health Campus, Coffs Harbour, New South Wales, Australia
🇦🇺Melanoma Institute Australia, North Sydney, New South Wales, Australia
A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-13
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 347
- Registration Number
- NCT05415215
- Locations
- 🇧🇦
University Clinical Center of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina
🇨🇷Clinica CIMCA, San José, Costa Rica
🇵🇪Instituto Regional de Enfermedades Neoplásicas del Sur; Centro de Inv. de Medicina Oncológica, Arequipa, Peru
Study To Evaluate The Efficacy And Safety Of Balovaptan In Adults With Post-Traumatic Stress Disorder (PTSD)
- Conditions
- Interventions
- First Posted Date
- 2022-06-02
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 29
- Registration Number
- NCT05401565
- Locations
- 🇺🇸
CITrials, Inc., Bellflower, California, United States
🇺🇸ASCLEPES Research Centers, Panorama City, California, United States
🇺🇸Clinical Innovations, Inc, Santa Ana, California, United States
Study to Evaluate The Safety and Efficacy of Balovaptan in Participants With Acute Ischemic Stroke at a High Risk of Developing Malignant Brain Edema
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT05399550
- Locations
- 🇺🇸
CPMC Comprehensive Stroke Care Center, San Francisco, California, United States
A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT05364424
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center UCI, Orange, California, United States
🇺🇸Memorial Cancer Institute at Memorial West, Pembroke Pines, Florida, United States
🇺🇸The University of Chicago, Chicago, Illinois, United States
An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 8
- Registration Number
- NCT05315713
- Locations
- 🇧🇪
Institut Jules Bordet, Bruxelles, Belgium
🇧🇪CHU UCL Namur - Mont-Godinne, Yvoir, Belgium
🇩🇪Universitaet Duisburg-Essen, Essen, Germany
A Study to Evaluate the Safety and Efficacy of Basmisanil Treatment in Children Aged 2-14 Years With Dup15q Syndrome
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 7
- Registration Number
- NCT05307679
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Rady Children's Hospital - San Diego, San Diego, California, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States